Schering Corporation

Merck Sharp + Dohme Corp.

Michael Eric Bigler

Joseph H Phillips

Linda Liang

Holly Cherwinski

Leonard G Presta

Daniel J Cua

Barbara Joyce-Shaikh

Drake LaFace

Robert H Pierce

Jennifer H Yearley

Patricia Bourne

Jonathon D Sedgwick

Kalyan Pande

Christopher John Gibson

Paul G Heyworth

Drake M Laface

The present disclosure provides antibodies and antigen binding fragments thereof including, but not limited to, monoclonal antibodies that specifically bind to human programmed death ligand 2 (PD-L2). The invention further provides nucleic acids encoding the antibodies and antigen binding fragments of the invention and host cells transformed therewith. The antibodies and antigen binding proteins of the invention are useful in methods for the immunohistochemical detection of human PD-L2 expression in tissue samples.

Antibody that binds to human programmed death ligand 2 (PD-L2) and uses thereof

The present disclosure provides isolated antibodies that specifically bind to human PD-L1, as well as antigen binding fragments of such antibodies, and kits comprising the anti-PD-L1 antibodies or binding fragments and a set of reagents for detecting a complex of the antibody, or antigen binding fragment thereof, bound to human PD-L1. The antibodies and antigen binding fragments of this disclosure are useful for immunohistochemical detection of human PD-L1 expression in tissue samples. Nucleic acid molecules encoding the antibodies and antigen binding fragments of this disclosure, as well as expression vectors and host cells for expression thereof, are also provided.

Antibodies that bind to human programmed death ligand 1 (PD-L1)

Provided are methods for modulating activity of the immune system using agonists or antagonists of a CD200 receptor. Also provided are methods of treatment and diagnosis of immune disorders.

Methods of modulating CD200 receptors

The invention relates generally to the field of immunology, in particular, to bispecific antibodies. Methods for designing a bispecific antibody for use in treating diseases relating to the immune system are disclosed. Specific examples relate to bispecific antibodies which recognize an activating receptor and an inhibiting receptor.

Use of bispecific antibodies to regulate immune responses

The present invention relates to methods for identifying and using modulators of FDF03 biological activity in vitro and in vivo that are useful in the treatment of cancer.

Methods for inhibiting tumor growth or reducing metastatic burden in a subject by administering FDF03 antibodies

Antibodies to human MDL-1 are provided, as well as uses thereof, e.g., in treatment of immune disorders, in particular, infectious diseases and sepsis.

Anti-MDL-1 antibodies

Growing community of inventors

Redwood City, CA, United States of America

Michael Eric Bigler